Evidence supporting the use of immune checkpoint inhibitors in the first-line setting for metastatic NSCLC first came from the KEYNOTE-024 trial, which compared pembrolizumab to chemotherapy in stage IV treatment-naive NSCLC patients with PD-L1 expressions ≥ 50% [6]. Here, CD274 is linked to non-small cell lung carcinoma.